Lewis A. Engman was an American lawyer, who served as the Chairman of the Federal Trade Commission from 21 February 1973 to 31 December 1975.
[1][2] He is also credited with being instrumental in passing legislation keeping in consistency with the interests of both Research-based and generic drug companies.
[4] He graduated from the University of Michigan in 1957 with high distinction,[4] where he was a member of Phi Beta Kappa.
For 25 years, he worked on issues like healthcare, regulation, competition and international economic policy.
He served as the chairman of the Blue Ribbon Committee on Generic Medicines, an independent panel which studied generic medicines and the Food and Drug Administration in 1990s.